What question did this study set out to answer?

The study aims to evaluate the diagnostic effectiveness of perfluorobutane contrast-enhanced ultrasound (PFB CEUS) compared to MRI in detecting small hepatocellular carcinoma (HCC) in high-risk patients.

March 5, 2026

Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018

Key Points

The study aims to evaluate the diagnostic effectiveness of perfluorobutane contrast-enhanced ultrasound (PFB CEUS) compared to MRI in detecting small hepatocellular carcinoma (HCC) in high-risk patients.
Multicenter retrospective design including high-risk patients
Patients underwent PFB CEUS and MRI
The study analyzed liver nodules 20 mm or smaller
Two CEUS strategies were compared with MRI using generalized estimating equations
Strategy B had higher sensitivity than Strategy A (65.9% vs 57.1%; P < .001)
No significant difference in sensitivity between Strategy B and MRI (65.9% vs 72.6%; P = .07)
Strategy B maintained high specificity compared to MRI (91.8% vs 90.5%; P = .59)
Both strategies showed higher specificity in patients without cirrhosis compared to those with cirrhosis (P = .04)

Abstract

Background Evidence supporting the incorporation of perfluorobutane (PFB) contrast-enhanced US (CEUS) into Liver Imaging Reporting and Data System (LI-RADS) in diagnosing small hepatocellular carcinoma (HCC) (≤20 mm) in patients at high risk for HCC remains limited. Purpose To compare diagnostic performance of PFB CEUS and MRI for small HCC in high-risk patients. Materials and Methods This multicenter retrospective study included high-risk patients who underwent PFB CEUS and concurrent MRI for evaluating liver nodules 20 mm or smaller from March 2020 to November 2023. PFB CEUS strategy A followed LR-5 criteria based on CEUS LI-RADS version 2017: observations that were at least 10 mm with nonrim arterial-phase hyperenhancement (APHE), with late and mild washout assessed up to 5 minutes postinjection; strategy B expanded on strategy A by also incorporating observations 10 mm or larger with nonrim APHE, no washout up to 5 minutes, and hypoenhancement on Kupffer-phase images. The diagnostic performance of these two CEUS strategies and MRI LI-RADS version 2018 was compared using a generalized estimating equations approach. Results A total of 365 patients (median age, 54 years; IQR, 47-61 years; 310 men) with 399 observations (median diameter, 16 mm; IQR, 12-19 mm; 252 HCCs, 41 non-HCC malignancies, 106 benign nodules) were included. Strategy B yielded higher sensitivity than strategy A (65.9% 166 of 252 vs 57.1% 144 of 252; P P = .07). Compared with MRI, strategy B showed no evidence of a difference in sensitivity (65.9% 166 of 252 vs 72.6% 183 of 252; P = .07) and specificity (91.8% 135 of 147 vs 90.5% 133 of 147; P = .59). Strategies A and B showed higher specificity (97.4% 76 of 78 vs 89.9% 62 of 69; 96.2% 75 of 78 vs 87.0% 60 of 69, respectively; both P = .04) but no evidence of a difference in sensitivity (54.8% 46 of 84 vs 58.3% 98 of 168 P = .63; 61.9% 52 of 84 vs 67.9% 114 of 168 P = .39, respectively) in patients without cirrhosis versus in patients with cirrhosis. Conclusion In patients at high risk for HCC, PFB CEUS incorporating Kupffer-phase findings was effective for diagnosing small HCC, with diagnostic performance similar to MRI. © RSNA, 2026 Supplemental material is available for this article.

AIに質問

Bookmark